|
EP2118117A2
|
|
Solid state forms of 5-azacytidine and processes for preparation thereof
|
|
WO2008002665A1
|
|
Regulation of acid metabolite production
|
|
EP1831347A1
|
|
INDUSTRIAL PRODUCING STRAIN OF THE FUNGUS CLAVICEPS PURPUREA (Fr.) Tul.
|
|
AU2006201547A1
|
|
Pharmaceutical compostions for oral and topical administration
|
|
WO2006099635A1
|
|
Isolation of galanthamine from biological material
|
|
MX2007011250A
|
|
Crystallization inhibitor and its use in gelatin capsules.
|
|
EP1805317A2
|
|
Process for isolation of macrolide compounds
|
|
BRPI0515695A
|
|
Process for isolation of crystalline tacrolimus
|
|
EP1778660A1
|
|
Process for the separation of paclitaxel and cephalomannin
|
|
EP1750701A1
|
|
Amorphous clopidogrel hydrochloride and its antithrombotic use
|
|
BRPI0506861A
|
|
process for isolation of crimping ergot alkaloids
|
|
EP1718644A1
|
|
Process for the manufacture of lysergic acid
|
|
GB0418580D0
|
|
Clopidogrel salt
|
|
GB0418395D0
|
|
Amorphous form of clopidogrel hydrochloride and its use as an antithrombotic compound
|
|
GB0412172D0
|
|
Amorphous form of clopidogrel hydrochloride and its use as an antithrombotic compound
|
|
KR20060028761A
|
|
Polymorphs of cabergoline
|
|
AU2003254754A1
|
|
Pharmaceutical compositions for oral and topical administration
|
|
CZ20013579A3
|
|
Isolation process of anthocyanin dyes from vegetable material
|
|
CZ20013153A3
|
|
Process for preparing silymarin exhibiting increased solubility
|
|
CZ20012071A3
|
|
Process for preparing mofetil mycophenolate
|
